P0453Association between Inflammatory Bowel Disease and Hidradenitis Suppurativa: An international multicenter retrospective study

Abstract IBD ENLIST Team: Benjamin Ungar Scott Stratman Lauren Lenz Diana Ruiz Susan Connor Amy Healey Bram Verstockt Sara El Ouali Anders Kirch Dige Corina Behrenbruch Christianne J. Busken Maria Manuela Estevinho Lucie Najman Background While studies have shown an association between inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS), the underlying mechanisms, clinical implications, and affected subpopulations remain poorly defined. ​​This multi-center study across sites in the U.S. and Europe seeks to assess the clinical, endoscopic, and dermatologic outcomes of patients with a diagnosis of both IBD and HS to better understand their association and to improve disease management. Methods A retrospective chart review was conducted across 10 health systems, including The Mount Sinai Hospital, Montefiore Einstein Medical Center, New York-Presbyterian/Weill Cornell Medical Center, New York University Langone Health, Humanitas Research Hospital, University of Nebraska Medical Center, Washington University School of Medicine, San Raffaele Hospital, Ghent University Hospital, and The University of British Columbia Hospital to identify patients with a diagnosis of IBD and HS. 264 patients were identified with confirmed diagnoses of IBD and HS. Clinical variables related to IBD and HS were collected, including demographics, comorbid conditions, markers of disease severity, and treatment. Results Of 264 patients with both IBD and HS, 78 were female (30%) and 184 were male (70%), with a median age of 38 years. The majority of patients had CD (n = 194, 74.6%). The median age at diagnosis of IBD was 23 years. The median age at diagnosis of HS was 30 years. IBD diagnosis preceded HS diagnosis in 189 patients (77.8%), whereas HS preceded IBD in 42 patients (17.3%). Eighty patients (30.3%) had extra-intestinal manifestations, most commonly peripheral arthritis (16.9%). Refractory disease requiring ≥ 3 advanced therapies was observed in 83 patients (32.2%), and 86 patients (34%) required intestinal surgery. Of all CD patients, 102 patients (56%) had perianal CD. Among perianal CD patients, 72 (80.9%) had Hurley stage 2 or 3 disease, compared with 45 (60.8%) of those with non-perianal CD. The presence of perianal CD was significantly associated with higher HS severity (odds ratio 2.73; 95% CI 1.35-5.52; p = 0.0046, chi-square test). Conclusion In this multicenter cohort of patients with IBD and HS, Crohn’s disease predominated, and IBD typically preceded the onset of HS by several years. A substantial proportion exhibited extraintestinal manifestations and refractory disease requiring multiple systemic therapies, highlighting the severe and treatment-resistant nature of disease in this population. There is a higher-than-expected proportion of perianal CD. The observed association between perianal CD and severe HS warrants further investigation to better understand this unique population and to identify shared pathogenic mechanisms. Reference: * The first two authors have contributed equally and are designated to have co-first authorship. Conflict of interest: Koseki Senda, Mako: None Cutrona, Marley: None O’hagan, Ross: none Rips, Aaron: None Faye, Adam S.: Consulting/Educational funding from: AbbVie, Takeda, Eli Lilly Deepak, Parakkal: Parakkal Deepak has received research support under a sponsored research agreement unrelated to the data in the abstract from AbbVie, Johnson and Johnson, Sanofi, Merck, Teva, Direct Biologics, Tr1x, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Roche Genentech, Eli Lilly, AstraZeneca, Spyre and Agomab, has received consulting fees from Johnson and Johnson, Abbvie, Merck, Sobi, Celltrion, Fresenius Kabi, Asahi Kasei Pharma, Sandoz and CorEvitas, LLC and has served on the board of the Srategic Alliance for Intercultural Advocacy in GI. Samaan, Sami: None Varadharajan, Ashvin: No conflicts of interest. Devi, Jalpa: none Thomas, Jacintha: I have no conflicts of interest to report. Hutchins, Kathryn: No conflict of interest Mannon, Peter: Nothing to declare Fite, Charlotte: Member of Boards and Investigator for industrial partners (UCB, Abbvie, Novartis, Janssen). Pommaret, Élise: None De Parades, Vincent: - Clinical research: Brothier, Sandoz, Takeda - Advisory boards: Abbvie - Courses, training, conferences: AAbbvie, Amgen, Biolitec, FCare Systems, Janssen, Takeda, THD lab, Tillots Fathallah, Nadia: Grant: A. Legrand AbbVie Amgen Biolitec Brothier FCare Systems Janssen Sandoz Takeda THD Lab Tillotts Pharma Mohan, Vivek: none Greywoode, Ruby: Research grant support from Janssen Scientific Affairs, Consultant to Sanofi. Geldof, Jeroen: Personal Fees: Jeroen Geldof has served as an advisory board member for Arena and as a speaker for Janssen and Galapagos. Truyens, Marie: na Lobatón Ortega, Triana: Grant: Abbvie, Ferring, Viatris, MSD, EG, Mundipharma, Biogen, Janssen, Pfizer, Takeda, Galapagos, Afasigma and Sandoz. Personal Fees: Speaker fees from MSD, Abbvie, Janssen, Amgen, Fresenius Kabi, Galapagos, Viatris, Ferring, Celltrion, Alfasigma, Lilly and Takeda. Consultancy fee from Janssen, Galapagos, Alfasigma, Amgen, Bristol Myers, Squibb Fresenius Kabi, Takeda and Abbvie Roth, Sydney: na Lukin, Dana: Consulting: Abbvie, Altrubio, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Palatin, Pfizer, Prime, PSI, Takeda, Vedanta. Grands: Boehringer Ingelheim, Johnson & Johnson Speaking: Abbvie, Johnson & Johnson Spinelli, Antonino: Personal Fees: Stryker, Johnson & Johnson, Arthrex Carvello, Michele: none De Zanet, Stefano: na Santana Gomes, Luana: na Williams, Astrid-Jane: na Sharma, Anmol: None Solitano, Virginia: Speaker’s fees from Pfizer, Takeda, Giuliani, Tillotts Pharma consulting fees from J & J travel grant from Abbvie Danese, Silvio: Personal Fees: AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB Inc., Vial, Vifor Lecture fees from Abbvie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, Takeda Agrawal, Manasi: None Colombel, Jean-Frédéric: Grant: AbbVie, Janssen Pharmaceuticals, Takeda, Prometheus and Bristol Myers Squibb Lectures from: AbbVie, Roche and Takeda Other: AbbVie, Amgen, AnaptysBio, Allergan, Apini, Arena Pharmaceuticals, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, candidrx Celgene, Celltrion, Clearview Curogen, Eli Lilly, Envision Pharma Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Roche, Janssen Pharmaceuticals, Kaleido Biosciences, Immunic, Iterative Scopes, Landos, Microba Life Science, Merck, Mirador, Novartis, Otsuka Pharmaceutical, Owkin, Pfizer, Protagonist Therapeutics, Sanofi, Sun Pharma, Takeda, Teva, TiGenix, and is holding stock options in Intestinal Biotech Development Cices, Ahuva: Ad Board Incyte, Novartis, LEO, Almirall, Bristol Meyers Squibb, Castle Biosciences, Primus, Janssen, Amgen, and Regeneron Consultant Fre Skincare and Botanix Speaker Sanofi Wong, Serre-Yu: Other: Research contract and support from Takeda/Trinetx and Eli Lilly and advisory board for Bristol Meyers Squibb